查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856700

血管栓塞市场按产品类型、应用和最终用户划分－2025年至2032年全球预测

Vascular Embolization Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，血管栓塞市场规模将达到 56.6 亿美元，复合年增长率为 11.76%。

关键市场统计数据
基准年 2024 23.2亿美元
预计年份：2025年 25.9亿美元
预测年份 2032 56.6亿美元
复合年增长率 (%) 11.76%

血管栓塞术简介：临床驱动因素、器械发展和手术整合正在塑造现代医疗保健服务。

血管栓塞术已从一项小众介入手术发展成为微创治疗多种血管和肿瘤疾病的基石。现代实践将设备创新与先进的影像引导技术相结合，能够比以往任何一代手术更精准、更安全地治疗动静脉畸形、肿瘤出血、子宫肌瘤和创伤性出血等疾病。本文概述了推动血管栓塞术在各种临床环境中广泛应用的临床驱动因素、技术进步和手术发展趋势。

导管技术和栓塞剂化学的快速发展正在重塑手术流程。操控性较佳、直径较小的微导管能够到达远端解剖结构，而从可脱卸弹簧圈到校准微球和液体栓塞剂等各种改良的栓塞剂，为外科医生提供了多种针对病变生理特征的栓塞选择。同时，术中影像技术的进步，包括锥状射束CT和融合导航，提高了病灶定位的准确性，并降低了非标靶栓塞的风险。这些进步对培训、器材采购和介入团队组成都产生了影响。

临床医生也积极应对患者期望的改变以及缩短住院时间和降低手术风险的系统性要求。因此，栓塞术正日益融入多学科诊疗路径，包括放射科、血管外科、肿瘤科和妇科。本节概述了栓塞术的临床原理、器械和技术演变以及操作环境，为后续更深入的分析奠定了基础，展现了栓塞术的不断成熟。

透过小型化、先进的影像技术以及整合的临床和商业模式，栓塞疗法正经历一场变革性的转变，并被重新定义。

栓塞治疗领域正在经历多方面的变革，涵盖临床实践、产品设计和商业策略。器械小型化和输送能力的提升使得以往难以触及的部位得以进入，从而拓展了治疗的可能性。同时，栓塞剂也朝着可预测、可调控的闭塞方向发展，液体製剂则能像模具一样渗透到复杂的血管床。这些进步共同改变了许多适应症的风险获益比，并迫使临床医生重新审视治疗流程。

影像保真度和手术规划的改进，以及材料和导管的创新，正在加速以主导为导向的决策。即时影像和术后检验工具降低了不确定性，并支持符合条件的患者当日出院，这反过来又影响了医院的运作效率和服务线的经济效益。此外，混合手术的兴起，即结合栓塞术和消融术、标靶全身性治疗等辅助疗法，正在催生新的跨学科临床通讯协定。

在商业性，製造商正透过整合设备、培训和疗效支援等提案，提供综合价值主张来因应市场变化。上市后监管和强调临床证据的法规正推动产品研发朝着可验证的安全性和长期疗效方向发展。相关人员应预期，基于价值的合约和临床疗效比较证据将在采购决策中发挥日益重要的作用，尤其是在医疗系统寻求能够提供稳定手术效果和可衡量后续获益的疗法时。

评估美国关税到2025年对供应链采购和临床采购动态的累积营运和策略影响

贸易政策发展和2025年前的关税措施正对栓塞治疗供应链的营运动态、筹资策略和临床应用产生多方面的影响。关税主导的成本压力促使医疗服务提供者和製造商重新评估其采购布局，并专注于地理多元化和严格的库存管理。製造商则透过考虑本地生产能力、区域分销中心和战略供应商协议来降低跨境贸易波动带来的风险。

从临床角度来看，关税的间接影响将反映在采购优先顺序的调整上。医疗系统，尤其是那些预算紧张的系统，可能会推迟择期手术，或转向采购落地成本较低的器械和耗材，这可能会影响新型器械和先进栓塞剂的引进时间。同时，由于临床团队优先考虑器械的可靠性和手术效果，关税带来的持续成本影响可能会导致与供应商旷日持久的谈判，以及为了平衡价格和临床效果而达成的附加条件采购协议。

从创新角度来看，製造商面临着在保护研发投资和管理生产经济效益之间寻求平衡的难题。如果製造商发现短期收入存在不确定性，关税导致的成本波动可能会延缓小众或高复杂度产品的商业化。另一方面，对供应链韧性的需求促使製造商投资于替代製造地和策略联盟，以实现关键零件的在地化生产。总体而言，关税动态凸显了供应链透明度、合约灵活性以及製造商、经销商和临床相关人员之间密切合作的战略重要性，以确保能够获得全方位的栓塞技术。

细分市场层面的洞察揭示了产品类型使用情况和最终用户动态如何影响临床应用的采购和策略优先排序。

对细分市场的详细分析阐明了临床需求、创新重点和采购决策的交汇点。依产品类型划分，器械分为附件、导管和栓塞剂。配件包括导管导引线、鞘套和注射器，这些配件有助于提高手术效率和安全性。导管分为大导管和微导管，二者的设计重点各不相同。大导管包括球囊导管和诊断导管，这些导管便于近端血管通路建立和血流控制。微导管则分为血流导引型微导管和附导线针对远端导航和标靶输送进行了最佳化。栓塞剂涵盖了广泛的化学成分，包括可脱卸和可推送的栓塞弹簧圈；液态栓塞剂，例如乙烯 - 乙烯醇和N-丁基氰基丙烯酸酯；以及提供校准或非校准频谱的微球，用于实现可预测的血管闭塞。以及用于暂时或永久性血管阻塞的颗粒剂，例如明胶海绵颗粒和聚乙烯醇颗粒。

针对特定应用场景的细分有助于明确临床应用案例，并为设备选择和培训需求提供基础。栓塞手术包括动静脉畸形（包括脑、週边和脊髓区域的亚型）；主要用于治疗咯血的支气管栓塞；肿瘤介入治疗，例如肝癌栓塞，以及需要快速肺动脉栓塞的消化道出血情况；肺栓塞（区分急性与慢性血栓栓塞性肺动脉高压）；创伤性出血管理；以及子宫肌瘤治疗（其中保留生育功能至关重要）。每种应用场景都对设备性能有特定的要求，并且对药物的持久性、控制和影像清晰度也有不同的预期。

门诊手术中心、医院和专科诊所的手术量、人员配备模式和资金限制各不相同。门诊手术中心着重手术效率和当日復健通讯协定，医院则需平衡急诊和择期手术的需求，而专科诊所通常集中手术专长，并作为特定适应症的卓越中心。了解产品类型、应用和最终使用者之间的相互关係，对于协调临床教育、供应链和商业性推广，从而与相关人员做出适当的决策至关重要。

地理因素影响美洲、欧洲、中东和非洲以及亚太地区招聘法规和基础设施的差异

区域动态对技术采纳轨迹、报销机制以及专业临床人才的可近性有显着影响。在美洲，成熟的介入放射学基础设施体现在其临床实践模式中，先进的影像技术和设备平台得到了广泛应用。这种环境有利于快速采用能够提高手术效率和患者吞吐量的设备，同时，不断发展的报销机制和基于价值的医疗服务模式也促使医疗机构在临床和经济效益方面取得切实可见的进步。

区域差异正在影响欧洲、中东和非洲的医疗服务取得和采购。欧洲一些资源丰富的中心正在引领新型栓塞剂和复杂手术组合的应用，而该地区的其他国家则优先考虑成本效益和供应的连续性。中东新兴的医疗中心正集中投资于三级医疗中心，而一些非洲国家则透过培训伙伴关係和有针对性的基础设施升级来提升医疗能力。这些不同的动态意味着，製造商和临床领导者必须使其实证医学研究和打入市场策略与次区域支付方的期望和采购惯例相适应。

亚太地区正经历快速的产能扩张，并高度重视与当地相关的临床数据和培训计画。手术量的增加、介入性心臟病学和放射学从业人员的扩充以及影像基础设施的投资，正在加速各种适应症的推广应用。然而，供应链的考量以及不同司法管辖区的监管差异，要求采取一种精细化的商业化策略，既要兼顾集中化的监管核准，又要兼顾针对特定国家的价值论证和临床医生教育工作。

老牌製造商与专业创新者之间的竞争行为：创新路径和合作策略塑造临床和商业竞争

栓塞领域的竞争动态取决于产品系列的广度、临床证据的累积以及提供能够降低手术复杂性的整合解决方案的能力。成熟的医疗设备製造商利用其全球分销网路和监管经验来扩大新型导管设计和栓塞剂的规模，而新兴的专业公司则透过专注于新型材料和平台技术的投资来推动创新。在这种由现有企业和利基创新者并存的竞争环境中，伙伴关係、授权协议和定向收购已成为加速产品临床应用的常见机制。

製造商越来越重视产品独立功能以外的差异化价值提案，包括临床医生培训、手术支援和数据主导的结果监测。参与真实世界证据计画和註册研究能够增强临床可信度，而与学术中心的合作则有助于改善设备适配和最佳实践技术。与经销商和医院集团采购组织的供应关係会影响通路动态，能够提供供应保障、透明定价模式和上市后监测支援的公司往往更容易获得采购合作伙伴的配合。

创新轨迹也体现了对辅助技术的推动，例如增强影像处理、更可控的栓塞输送系统以及将栓塞与生物活性或靶向有效载荷相结合的新一代药物。随着支付方和相关人员要求证明患者获益，能够高效产生可靠的临床结果数据并将产品开发与相关人员需求相结合的公司，将在这个不断变化的环境中占据有利地位，保持竞争优势。

为产业领导者提供切实可行的策略建议，以增强供应链韧性、加速产品应用，并使采购重点与临床价值保持一致。

产业领导者应优先考虑一系列切实可行的策略，以最大限度地提高栓塞治疗的临床疗效和商业性韧性。首先，应投资于供应链的透明度和多元化，以降低跨境贸易中断和关税波动带来的风险。本地库存和关键部件的多元化采购将有助于增强营运连续性，并支援对临床需求的快速反应。

其次，我们将透过深化与高流量中心和多学科团队的伙伴关係，开发符合临床医师主导应用情境的产品。我们将共同製定操作规程和训练课程，确保结果可重复，并缩短先进设备的学习曲线。这种方法将有助于提高临床医生的认可度，并加速在各种终端使用者环境中安全应用。

第三，将证据产生计画纳入您的商业化时间表。完善的临床註册研究和能够捕捉功能性结果、併发症发生率和资源利用情况的实用性真实世界研究，将有助于您与支付方和医院采购委员会展开讨论。重点关注对临床医生和管理者都至关重要的结果，例如缩短住院时间和减少再次手术的需求。

最后，考虑将设备、培训和结果支援相结合的捆绑式价值提案，以在竞争激烈的采购环境中脱颖而出。儘早与临床和采购相关人员接洽，共同製定服务水准协议和售后支援模式，将有助于加强长期伙伴关係，并根据现场回馈不断改进产品。

一份可重复且透明的调查方法，概述了支持报告结论的主要研究、文献综述、分析方法和检验步骤。

本研究整合了主要相关人员访谈、同行评审的临床文献、监管文件、手术操作指南和器械标籤讯息，建构了一个可重复的分析基础。主要资料来源包括对各专科介入临床医生、门诊手术中心和医院的采购负责人以及产品开发主管进行的结构化访谈，以了解不同地区的手术偏好、预期器械性能和采购考虑。次要分析则依赖已发表的临床研究、共识声明和器械性能报告，以验证临床医生的意见与已记录的安全性和有效性结果。

分析方法包括对访谈记录进行定性主题编码和比较设备功能映射，以识别反覆出现的临床需求和设计权衡。区域采用趋势分析依赖公立医院登记处报告的手术量趋势以及专业协会指南（如有）。供应链评估结合了供应商资讯和公开的贸易及监管数据，以评估潜在的风险点。检验步骤包括将临床医师报告的实务模式与手术层面的证据进行交叉比对，并邀请资深介入专家进行专家评审，以确保临床有效性。

此方法强调透明度，关键假设、纳入标准以及主要和次要来源均记录在技术附录中。这种结构便于读者復现分析步骤、查阅资料，并根据自身机构的具体问题或后续研究活动调整框架。

简明扼要的结论总结了技术、临床和操作方面的优先事项，旨在指南栓塞治疗相关相关人员的策略决策。

结论综合了临床需求、器械创新和操作限制相互作用所涌现的核心主题。栓塞术已进入一个阶段，渐进式设计改进和新型栓塞剂大大扩展了治疗手段，使临床医生能够更有信心地治疗更复杂的解剖结构。同时，影像学和手术相关训练的进步正在缩短学习曲线，提高安全性，并加强栓塞术在多学科诊疗路径中的作用。

在营运层面，供应链韧性和基于证据的价值论证将决定技术应用的速度和模式。积极追求采购透明度、降低区域供应风险并产生以结果为导向的证据的製造商和医疗服务提供者，将更有能力应对多样化的医疗环境。关税相关的压力以及报销和基础设施方面的区域差异，将要求制定适应性策略，以平衡短期成本控制与对临床检验和临床医生参与的长期投资。

最终，该领域的发展趋势倾向于将设备性能、手术支援和可证实的临床价值相结合的整合解决方案。将产品开发与临床医生的工作流程相协调、优先考虑高品质证据并保持灵活的商业和生产模式的相关人员，将创造可持续的竞争优势并改善患者的治疗效果。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 用于标靶化疗栓塞治疗的可生物降解微球的扩展。
  • 整合先进的影像导引系统以提高栓塞术的准确性
  • 液体栓塞剂在治疗週边动脉阻塞的应用日益广泛
  • 开发用于增强手术过程中透视可见性的渗透性
  • 3D血管模型在血管栓塞术前规划与训练的应用日益广泛
  • 人工智慧驱动的栓塞剂选择和手术结果预测软体的出现

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的血管栓塞市场

  • 配件
    • 导管导引线
    • 鞘套
    • 注射器
  • 导管
    • 大导管
      • 球囊导管
      • 诊断导管
    • 微导管
      • 直流式微导管
      • 附导线式微导管
  • 栓塞剂
    • 栓塞线圈
      • 可拆卸线圈
      • 可推式线圈
    • 液态栓塞剂
      • 乙烯 - 乙烯醇共聚物
      • N-丁基氰基丙烯酸酯
    • 微球
      • 校准微球
      • 未校准的微球
    • 颗粒栓塞剂
      • 明胶海绵颗粒
      • 聚乙烯醇颗粒

9. 按应用分類的血管栓塞市场

  • 动静脉畸形
    • 脑动静脉畸形
    • 週边动静脉畸形
    • 脊髓动静脉畸形
  • 支气管栓塞
    • 咯血管理
  • 消化道出血
  • 肝癌
  • 肺栓塞
    • 急性肺动脉栓塞
    • 慢性血栓栓塞性肺动脉高压
  • 创伤管理
  • 子宫肌瘤

第十章 依最终用户分類的血管栓塞市场

  • 门诊手术中心
  • 医院
  • 专科诊所

第十一章 区域血管栓塞市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 血管栓塞市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国血管栓塞市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Terumo Corporation
    • Boston Scientific Corporation
    • Medtronic plc
    • Johnson & Johnson
    • Stryker Corporation
    • Merit Medical Systems, Inc.
    • Cook Medical LLC
    • Penumbra, Inc.
    • B. Braun Melsungen AG
    • Becton Dickinson and Company
Product Code: MRR-742BD5184D4D

The Vascular Embolization Market is projected to grow by USD 5.66 billion at a CAGR of 11.76% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.32 billion
Estimated Year [2025] USD 2.59 billion
Forecast Year [2032] USD 5.66 billion
CAGR (%) 11.76%

Foundational introduction to vascular embolization delineating clinical drivers, device evolution, and procedural integration shaping contemporary care delivery

Vascular embolization has evolved from a niche interventional procedure into a cornerstone of minimally invasive therapy for a wide range of vascular and oncologic conditions. Contemporary practice blends device innovation with advanced image guidance, enabling clinicians to treat arteriovenous malformations, oncologic bleeding, uterine fibroids, and traumatic hemorrhage with greater precision and safety than earlier generations of techniques. This introduction frames the clinical drivers, technological enablers, and procedural trends that are accelerating adoption across diverse care settings.

Rapid progress in catheter technology and embolic agent chemistry is redefining procedural workflows. Improved navigability and smaller profile microcatheters allow access to distal anatomy, while refined embolic agents-from detachable coils to calibrated microspheres and liquid agents-provide operators with a broader spectrum of occlusion options tailored to lesion physiology. Concurrent advances in intraprocedural imaging, including cone beam CT and fusion-based navigation, increase lesion localization accuracy and reduce non-target embolization risk. These developments have implications for training, procurement, and interventional team composition.

Clinicians are also responding to changing patient expectations and system-level imperatives to shorten hospital stays and reduce procedural risk. As such, embolization is increasingly integrated into multidisciplinary care pathways involving radiology, vascular surgery, oncology, and gynecology. This section sets the stage for deeper analysis by outlining the clinical rationale, device and procedural evolution, and the operational context in which embolization continues to mature.

Transformative shifts redefining embolization therapy driven by device miniaturization, imaging precision, and integrated clinical and commercial models

The landscape of embolization is undergoing several transformative shifts that touch clinical practice, product design, and commercial strategy. Device miniaturization paired with enhanced deliverability is enabling access to previously untreatable anatomies and expanding the therapeutic envelope. This technical evolution is complemented by a move toward embolic agents that provide predictable, calibrated occlusion and by liquid formulations that offer cast-like penetration for complex vascular beds. Together, these advances are shifting the risk-benefit calculus for many indications and prompting clinicians to revisit treatment algorithms.

Parallel to material and catheter innovation, improvements in imaging fidelity and procedural planning are accelerating procedurally driven decision-making. Real-time imaging and post-deployment verification tools reduce uncertainty and support same-day discharge pathways in appropriate patients, which in turn influences hospital throughput and service line economics. Moreover, the rise of hybrid procedures that combine embolization with adjunctive therapies, such as ablation or targeted systemic treatment, is creating new interdisciplinary clinical protocols.

Commercially, manufacturers are responding with integrated value propositions that bundle devices, training, and outcomes support. Regulatory emphasis on post-market surveillance and clinical evidence is steering product development toward demonstrable safety and long-term performance. Stakeholders should anticipate that value-based contracting and evidence of comparative clinical effectiveness will play an increasingly prominent role in procurement decisions, especially as health systems seek therapies that deliver consistent procedural outcomes with measurable downstream benefits.

Assessment of cumulative operational and strategic impacts from United States tariff measures through 2025 on supply chains sourcing and clinical procurement dynamics

Trade policy developments and tariff measures introduced through 2025 have had a multifaceted influence on the operational dynamics of embolization supply chains, procurement strategies, and clinical access. Tariff-driven cost pressures have prompted healthcare providers and manufacturers to reassess sourcing footprints, with an emphasis on geographic diversification and closer inventory management. Manufacturers have responded by examining localized production capacity, regional distribution hubs, and strategic supplier contracts to mitigate exposure to cross-border trade variability.

Clinically, the indirect effects of tariffs manifest through procurement prioritization. Health systems, particularly those operating under tight budgetary constraints, may defer elective procedures or shift toward devices and consumables with lower landed costs, which can influence the adoption timing of newer device classes and advanced embolic agents. At the same time, clinical teams prioritize device reliability and procedural performance, so sustained tariff-related cost implications can lead to longer-term supplier negotiations and conditional purchasing arrangements that balance price with clinical outcomes.

From an innovation perspective, manufacturers face a balancing act between safeguarding R&D investment and managing production economics. Tariff-induced cost volatility can slow the commercialization timeline for niche or high-complexity products if manufacturers deem near-term returns uncertain. Conversely, the need for supply chain resilience has spurred investments in alternate manufacturing sites and in strategic partnerships that localize critical component production. Overall, tariff dynamics reinforce the strategic importance of supply chain transparency, contractual flexibility, and close collaboration among manufacturers, distributors, and clinical stakeholders to preserve access to the full range of embolization technologies.

Segment-level insights clarifying how product type application and end-user dynamics influence clinical adoption procurement and strategic prioritization

A granular view of segmentation clarifies where clinical demand, innovation focus, and purchasing decision-making converge. Across product types, devices are categorized into accessories, catheters, and embolic agents; accessories encompass guide wires, sheaths, and syringes that support procedural efficiency and safety, while catheters divide into macrocatheters and microcatheters, each with distinct design priorities. Macrocatheters include balloon catheters and diagnostic catheters that facilitate proximal vessel access and flow control, whereas microcatheters split into flow-directed microcatheters and over-the-wire microcatheters optimized for distal navigation and targeted delivery. Embolic agents represent a broad chemistry spectrum, including embolic coils that are available as detachable or pushable variants, liquid embolic agents such as ethylene vinyl alcohol copolymer and N-butyl cyanoacrylate that provide cast-like penetration, microspheres offered as calibrated or non-calibrated formulations for predictable occlusion, and particulate agents including gelatin sponge particles and polyvinyl alcohol particles used for temporary or permanent vessel occlusion.

Application-focused segmentation delineates clinical use cases and informs device selection and training needs. Embolization procedures address arteriovenous malformations with subtypes in brain, peripheral, and spinal territories, bronchial embolization primarily targeting hemoptysis management, gastrointestinal bleeding scenarios where rapid hemostasis is critical, oncologic interventions such as liver cancer embolotherapy, pulmonary embolization that differentiates acute pulmonary embolism from chronic thromboembolic pulmonary hypertension, trauma-focused hemorrhage control, and uterine fibroid management where fertility-preserving options matter. Each application imposes particular device performance requirements and varying expectations for agent permanence, control, and imaging visibility.

End-user segmentation affects procurement timelines and adoption curves, with ambulatory surgical centers, hospitals, and specialty clinics each presenting different procedural volumes, staffing models, and capital constraints. Ambulatory surgical centers emphasize throughput and same-day recovery protocols, hospitals balance acute and elective demand across higher acuity cases, and specialty clinics often concentrate procedural expertise and serve as centers of excellence for defined indications. Understanding the interplay among product type, application, and end user is essential for aligning clinical education, supply arrangements, and commercial outreach to the right decision-making stakeholders.

Geographic dynamics shaping adoption regulatory and infrastructure distinctions across the Americas Europe Middle East & Africa and Asia-Pacific regions

Regional dynamics exert a powerful influence on technology adoption pathways, reimbursement frameworks, and the availability of specialized clinical expertise. In the Americas, practice patterns reflect a mature interventional radiology infrastructure with broad uptake of advanced imaging and device platforms, and care delivery models that increasingly emphasize outpatient pathways and bundled clinical programs. This environment supports rapid iteration of devices that enhance procedural efficiency and patient throughput, while reimbursement evolution and value-based care initiatives push providers to demonstrate tangible improvements in clinical and economic outcomes.

In Europe, Middle East & Africa, regional heterogeneity shapes access and procurement. High-resource centers in parts of Europe lead in adoption of novel embolic agents and complex procedural combinations, while other countries within the region prioritize cost-effectiveness and supply continuity. Emerging hubs in the Middle East concentrate investments in tertiary centers of excellence, and select countries in Africa are building capacity through training partnerships and targeted infrastructure upgrades. These diverse dynamics mean that manufacturers and clinical leaders must tailor evidence generation and market access strategies to subregional payer expectations and procurement practices.

The Asia-Pacific region presents rapid capacity expansion and a strong emphasis on locally relevant clinical data and training programs. Growing procedural volumes, expanding interventional cardiology and radiology workforces, and investments in imaging infrastructure are accelerating adoption across a range of indications. However, supply chain considerations and regulatory variability across jurisdictions require nuanced commercialization approaches that balance centralized regulatory approvals with country-specific value demonstration and clinician education efforts.

Competitive behavior innovation pathways and partnership strategies among established manufacturers and specialized innovators shaping clinical and commercial competition

Competitive dynamics in the embolization space are defined by product portfolio breadth, clinical evidence generation, and the ability to deliver integrated solutions that reduce procedural complexity. Established medical device companies leverage global distribution networks and regulatory experience to scale new catheter designs and embolic chemistries, while emerging specialized firms drive innovation through focused investments in novel materials and platform technologies. This mix of incumbents and niche innovators creates a competitive environment where partnerships, licensing arrangements, and targeted acquisitions are common mechanisms to accelerate time to clinical adoption.

Manufacturers are increasingly emphasizing differentiated value propositions that go beyond single-product features to include clinician training, procedural support, and data-driven outcomes monitoring. Real-world evidence programs and registry participation strengthen clinical credibility, and collaborations with academic centers help refine device indications and best-practice techniques. Supply relationships with distributors and hospital group purchasing organizations influence channel dynamics, and firms that can offer supply assurance, transparent pricing models, and post-market surveillance support tend to find more receptive procurement partners.

Innovation pathways also reflect a push toward adjunctive technologies such as imaging enhancements, embolic delivery systems with improved control, and next-generation agents that combine embolic occlusion with bioactive or targeted payloads. As payers and providers look for demonstrable patient benefits, the companies that can efficiently generate robust clinical outcomes data and align product development with stakeholder needs will maintain a competitive advantage in the evolving landscape.

Actionable strategic recommendations for industry leaders to strengthen supply resilience accelerate adoption and align clinical value with procurement priorities

Industry leaders should prioritize a set of actionable strategies to maximize clinical impact and commercial resilience in embolization therapy. First, invest in supply chain transparency and diversification to reduce exposure to cross-border trade disruptions and tariff fluctuations. Localized inventory hubs and multi-sourcing of critical components will enhance operational continuity and support rapid clinical demand responsiveness.

Second, align product development with clinician-driven use cases by deepening partnerships with high-volume centers and multidisciplinary teams. Co-develop procedural protocols and training curricula that demonstrate reproducible outcomes and shorten the learning curve for advanced devices. This approach fosters clinician advocacy and accelerates safe adoption across varied end-user settings.

Third, integrate evidence-generation plans into commercialization timelines. Robust clinical registries and pragmatic real-world studies that capture functional outcomes, complication rates, and resource utilization will facilitate discussions with payers and hospital procurement committees. Emphasize outcomes that matter to both clinicians and administrators, such as reduced hospital length of stay and decreased need for repeat procedures.

Finally, consider bundled value propositions that combine devices, education, and outcomes support to differentiate offerings in competitive procurement environments. Engaging early with clinical and procurement stakeholders to co-create service-level agreements and post-sale support models will strengthen long-term partnerships and create pathways for iterative product improvements based on frontline feedback.

Transparent reproducible research methodology outlining primary interviews literature review analytical frameworks and validation steps supporting the report findings

This research synthesizes primary stakeholder interviews, peer-reviewed clinical literature, regulatory filings, procedural practice guidelines, and device labeling information to produce a reproducible analytical foundation. Primary inputs included structured interviews with interventional clinicians across specialties, procurement leaders from ambulatory surgical centers and hospitals, and product development executives; these interviews were conducted to capture procedural preferences, device performance expectations, and procurement considerations across geographic regions. Secondary analysis relied on published clinical studies, consensus statements, and device performance reports to triangulate clinician perspectives with documented safety and efficacy outcomes.

Analytical methods incorporated qualitative thematic coding of interview transcripts and comparative device feature mapping to identify recurring clinical needs and design trade-offs. Regional adoption analyses were informed by procedural volume trends reported in public hospital registries and professional society guidance where available, while supply chain assessments combined supplier mapping with publicly available trade and regulatory data to evaluate potential exposure points. Validation steps included cross-referencing clinician-reported practice patterns with procedure-level evidence and soliciting expert review from senior interventional practitioners to ensure clinical plausibility.

The methodology emphasizes transparency: key assumptions, inclusion criteria, and the provenance of primary and secondary sources are documented in the technical appendix. This structure allows readers to replicate analytical steps, interrogate source material, and adapt the framework to institution-specific questions or follow-up research activities.

Concise conclusion synthesizing technological clinical and operational priorities that should guide strategic decision-making across embolization stakeholders

The conclusion synthesizes the core themes that emerge from the interplay of clinical needs, device innovation, and operational constraints. Embolization has entered a phase where incremental design improvements and novel embolic chemistries materially expand the therapeutic repertoire, enabling clinicians to treat more complex anatomies with greater confidence. Concurrently, imaging advances and procedure-focused training shorten learning curves and enhance safety, reinforcing embolization's role in multidisciplinary care pathways.

Operationally, supply chain resilience and evidence-based value demonstration will shape the pace and pattern of adoption. Manufacturers and providers that proactively address procurement transparency, localized supply risk mitigation, and outcomes-oriented evidence generation will be better positioned to serve diverse care settings. Tariff-related pressures and regional heterogeneity in reimbursement and infrastructure require adaptive strategies that balance near-term cost management with longer-term investments in clinical validation and clinician engagement.

Ultimately, the field's trajectory favors integrated solutions that combine device performance, procedural support, and demonstrable clinical value. Stakeholders who align product development with clinician workflows, prioritize high-quality evidence, and maintain flexible commercial and manufacturing models will create durable competitive advantages and improve patient-level outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of biodegradable microspheres for targeted chemoembolization therapies
  • 5.2. Integration of advanced imaging guidance systems to improve embolization accuracy
  • 5.3. Rising adoption of liquid embolic agents in peripheral arterial occlusion treatments
  • 5.4. Development of radiopaque microspheres enhancing fluoroscopic visibility during procedures
  • 5.5. Increasing use of three-dimensional printed vascular models for preprocedural embolization planning and training
  • 5.6. Emergence of AI-driven software for embolic agent selection and procedural outcome prediction

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Embolization Market, by Product Type

  • 8.1. Accessories
    • 8.1.1. Guide Wires
    • 8.1.2. Sheaths
    • 8.1.3. Syringes
  • 8.2. Catheters
    • 8.2.1. Macrocatheters
      • 8.2.1.1. Balloon Catheters
      • 8.2.1.2. Diagnostic Catheters
    • 8.2.2. Microcatheters
      • 8.2.2.1. Flow Directed Microcatheters
      • 8.2.2.2. Over The Wire Microcatheters
  • 8.3. Embolic Agents
    • 8.3.1. Embolic Coils
      • 8.3.1.1. Detachable Coils
      • 8.3.1.2. Pushable Coils
    • 8.3.2. Liquid Embolic Agents
      • 8.3.2.1. Ethylene Vinyl Alcohol Copolymer
      • 8.3.2.2. N-Butyl Cyanoacrylate
    • 8.3.3. Microspheres
      • 8.3.3.1. Calibrated Microspheres
      • 8.3.3.2. Non-Calibrated Microspheres
    • 8.3.4. Particulate Embolic Agents
      • 8.3.4.1. Gelatin Sponge Particles
      • 8.3.4.2. Polyvinyl Alcohol Particles

9. Vascular Embolization Market, by Application

  • 9.1. Arteriovenous Malformations
    • 9.1.1. Brain Arteriovenous Malformations
    • 9.1.2. Peripheral Arteriovenous Malformations
    • 9.1.3. Spinal Arteriovenous Malformations
  • 9.2. Bronchial Embolization
    • 9.2.1. Hemoptysis Management
  • 9.3. Gastrointestinal Bleeding
  • 9.4. Liver Cancer
  • 9.5. Pulmonary Embolization
    • 9.5.1. Acute Pulmonary Embolism
    • 9.5.2. Chronic Thromboembolic Pulmonary Hypertension
  • 9.6. Trauma Management
  • 9.7. Uterine Fibroids

10. Vascular Embolization Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Vascular Embolization Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Vascular Embolization Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Vascular Embolization Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Terumo Corporation
    • 14.3.2. Boston Scientific Corporation
    • 14.3.3. Medtronic plc
    • 14.3.4. Johnson & Johnson
    • 14.3.5. Stryker Corporation
    • 14.3.6. Merit Medical Systems, Inc.
    • 14.3.7. Cook Medical LLC
    • 14.3.8. Penumbra, Inc.
    • 14.3.9. B. Braun Melsungen AG
    • 14.3.10. Becton Dickinson and Company

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. VASCULAR EMBOLIZATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. VASCULAR EMBOLIZATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VASCULAR EMBOLIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GUIDE WIRES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SHEATHS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BALLOON CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY FLOW DIRECTED MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY OVER THE WIRE MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CALIBRATED MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY NON-CALIBRATED MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GELATIN SPONGE PARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY POLYVINYL ALCOHOL PARTICLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRAIN ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PERIPHERAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPINAL ARTERIOVENOUS MALFORMATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY BRONCHIAL EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HEMOPTYSIS MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY GASTROINTESTINAL BLEEDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY PULMONARY EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY ACUTE PULMONARY EMBOLISM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY TRAUMA MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY UTERINE FIBROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL VASCULAR EMBOLIZATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY ACCESSORIES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY CATHETERS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MACROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY EMBOLIC COILS, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY MICROSPHERES, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS VASCULAR EMBOLIZATION MARKET SIZE, B